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Abstract Treatment of chronic lymphocytic leukemia
(CLL) has advanced wi th the in t roduc t ion o f
chemoimmunotherapy (CIT) agents that have improved
the outcomes of frontline therapy. However, most treated
patients will relapse and require subsequent therapy. This
review focuses on recent advances in the treatment of
relapsed or refractory CLL. Until recently, treatment op-
tions for relapsed CLL were of limited efficacy.
Retreatment with fludarabine, cyclophosphamide, and ri-
tuximab (FCR) was recommended for patients with a du-
rable response to first-line FCR, although acquired genetic
aberrations, impaired marrow reserve, and comorbidities
often made this suboptimal therapy for many patients.
New options include two agents targeting B cell receptor
(BCR) signaling pathways (ibrutinib and idelalisib) and a
B cell lymphoma-2 (BCL-2) inhibitor (venetoclax).
Allogeneic hematopoietic stem cell transplantation
(HSCT) remains a potentially curative option for younger
patients with a suitable donor.
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Introduction
Recent progress in the treatment of chronic lymphocytic leu-
kemia (CLL) has been dramatic with the introduction of sev-
eral novel agents. The addition of an anti-CD20 monoclonal
antibody to frontline chemotherapy (chemoimmunotherapy
[CIT]) results in improved progression-free survival (PFS)
and overall survival (OS) compared to chemotherapy alone
[1, 2]. However, even with excellent responses to frontline
therapy, most patients will relapse with the need for subse-
quent treatment. The focus of this review will be on recent
advances in the treatment of relapsed or refractory CLL.
Chronic lymphocytic leukemia is the most common
lymphoproliferative disorder in adults, with an age-
adjusted incidence of 4.8 to 5.0 per 100,000 person-
years [3, 4] and a median age at diagnosis of 72 years
[5]. Staging systems using clinical (adenopathy/
organomegaly) and hematologic (anemia and thrombocy-
topenia) parameters remain useful in stratifying patients in
this disease, which has a variable clinical course and a
survival that may range from 18 months to more than
20 years [5, 6].
Although distinguished by a diagnostic immunophenotype,
CLL has been characterized as a heterogeneous disease
by genetic and molecular studies. These have identified useful
prognostic and predictive variables correlating with the tempo
of disease progression and survival, as well as response to
therapy. Cytogenetic testing by fluorescence in situ hybridiza-
tion (FISH) can detect several recurrent genetic aberrations in
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CLLwith themost frequent abnormalities at diagnosis being
13q deletion (55% of patients), which is associated with a
favorable prognosis; 11q deletion (18%) and 17p deletion
(7% in previously untreated patients and about 30% in
relapsed/refractorypatients),bothassociatedwithamorerap-
idly progressive course and shorter survival; and trisomy 12
(16%), associated with an intermediate prognosis [7]. DNA
studies of immunoglobulin genes in CLL have also defined
twosubsets ofCLLwithmutatedorunmutated immunoglob-
ulin heavy-chain variable (IGHV) regions based on sequence
homology with germ line IGHV genes. Patients with
unmutated IGHV have a shorter time to first treatment and
PFS following CIT than patients with mutated IGHV. Zeta
chain-associated protein kinase 70 kD (ZAP-70) impacts B
cell receptor (BCR) signaling, proliferation, and migration
and is predominantly expressed in the unmutated genotype,
although it is not a reliable surrogate for unmutated IGHV
status. Genomic studies have identified mutations involving
notchhomolog1 (NOTCH1)andsplicing factor3b, subunit1
(SF3B1), which also appear to predict a shorter time to treat-
ment failure and reduced OS [8]. Telomere length has been
showntobea robust independentpredictorofCLLoutcomes,
including OS and Richter’s transformation (transformation
into a more aggressive large B cell lymphoma) [9]. An
International Prognostic Index for CLL (CLL-IPI) incorpo-
ratingfive independentprognostic features (TP53status,age,
clinicalstage,IGHVmutationalstatus,andβ2-microglobulin
level) has recently been developed to allow more targeted
CLLpatientmanagementinclinicalpracticeandclinicaltrials
[10].Usingaweightedgradingofthesefactors,it identifiesthe
following four risk groups with significantly different OS at
5 years: low (93.2%), intermediate (79.3%), high (63.3%),
and very high (23.3%) risk.
Currently used therapies
Treatment of CLL is often deferred in asymptomatic, early-
stage patients and initiated in the presence of signs or symp-
toms outlined by the International Workshop on CLL
(IWCLL) criteria [11]. The choice of frontline CLL therapy
is influenced by patient age and fitness. Aside from Eastern
Cooperative Oncology Group (ECOG) performance status, an
approach to formal evaluation of the latter has been the
Cumulative Illness Rating Scale (CIRS), which rates comor-
bidities that may affect tolerability and toxicity of different
regimens. With a wider range of therapeutic options now
available, categorization of patients based on age (≥ or <65,
70, or 75 years), creatinine clearance (< or ≥70 mL/min), and
fitness assessment has become important in the choice of ther-
apy. Improvement in PFS and OS are common goals of ther-
apy, but the risk/benefit ratio of different regimens may be
distinct for different risk groups. In younger patients who are
better able to tolerate more myelosuppressive regimens, a
more intensive approach may be justified, whereas the prima-
ry objective in an elderly population may be quality of life
with less focus on OS. In chemoimmunotherapy trials, com-
plete response (by IWCLL criteria [11]) and achievement of
minimal residual disease (MRD) status (<10−4 CLL cells de-
tected by multiparameter flow cytometry) are correlated with
PFS and OS prolongation. Although MRD negativity may be
a clinically important endpoint in potentially curative strate-
gies and in the design of maintenance therapy trials, MRD
analysis is not routine in the current standard of care and
remains investigational.
Randomized trials have established the combination of
fludarabine, cyclophosphamide, and rituximab (FCR) as the
frontline standard of care in a younger population with few
comorbidities [1, 12]. A 10-year follow-up of 300 patients
treated with FCR at MD Anderson Cancer Center indicated
a sustained PFS in a subset of patients, with 42 patients
experiencing no relapses beyond 10.4 years [13]. The best
results were noted in patients lacking poor-risk FISH aberra-
tions and with mutated IGHV. Older age (≥70 years) was as-
sociated with a lower rate of complete remission (CR; 51 vs.
76% in younger patients), and 54% of older patients did not
complete the planned 6 cycles of therapy due to persistent
cytopenias [14]. Based on a phase 2 study of bendamustine
plus rituximab (BR) [15], the German CLL group conducted a
phase 3 study comparing FCR to BR in previously untreated
fit patients (CIRS score ≤6, creatinine clearance ≥70 mL/min)
[16]. Although treatment with FCRwas superior to BR overall
for PFS (median 55.2 vs. 41.7 months; p = 0.0003, hazard
ratio [HR] 1.643), no difference in overall survival was ob-
served with a median follow-up of 37.1 months. Furthermore,
hematologic toxicity and infectious complications were more
pronounced with FCR in patients >65 years, and with con-
cerns about protracted immunosuppression with FCR, the
combination of bendamustine plus rituximab can be consid-
ered an acceptable treatment option for fit patients in this age
group. A phase 3 trial in untreated CLL patients with a CIRS
score >6 or a creatinine clearance of 30 to 60 mL/min ran-
domized 781 patients with a median age of 73 years to treat-
ment with chlorambucil (CLB), chlorambucil with rituximab,
or chlorambucil with obinutuzumab, a humanized
glycoengineered type 2 anti-CD20 MoAb. The latter combi-
nation resulted in improved OS compared to CLB and supe-
rior PFS and CR rate compared to CLB-rituximab [17] and
currently defines the standard of care for this population of
patients. Similarly, a phase 3 study comparing the combina-
tion of ofatumumab, an anti-CD20 that binds to a different
epitope, and chlorambucil to chlorambucil alone confirmed
the benefit of the combination in improving PFS in this pop-
ulation (22.4 vs. 13.1 months; p < 0.001) [18].
The decision to initiate therapy for relapsed CLL is based
on the same considerations as for frontline treatment, although
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observation (i.e., Bwatch and wait^) in patients with slowly
progressive lymphocytosis as the only disease manifestation
may require closer monitoring than in untreated patients. Until
the recent development of kinase inhibitors targeting B cell
signaling pathways, treatment options in this population were
of limited efficacy. The benefit of adding rituximab to FC in
previously treated patients was shown in the REACH trial
comparing FCR to FC with improved PFS in the CIT arm
(median 30.6 vs. 20.6 months) [2]. Comparable results were
observed in the COMPLEMENT 2 trial with the addition of
ofatumumab to FC (median 28.9 vs. 18.8 months) [19]. These
combinations might be considered for appropriate patients
with limited prior therapies, and retreatment with FCR may
be effective in patients with a durable response to frontline
FCR (progression-free interval exceeding 24–36 months);
however, bone marrow suppression is frequent and the dura-
tion of a second response is predictably shorter. Further com-
plicating treatment in this setting is the observation of del
(17p) and TP53 mutation (by sequence analysis) in ~30% of
relapsed patients post-FCR [20, 21], which predicts poor re-
sponse to retreatment with purine nucleosides and alkylating
agents. Impaired marrow reserve resulting from previous che-
motherapy and additional comorbidities as a consequence of
progression of disease and advancing age must also be con-
sidered in this setting.
In the minority of patients who are young and fit enough to
be eligible, allogeneic hematopoietic stem cell transplantation
(allo HSCT), harnessing a Bgraft vs. leukemia^ effect, offers
the best chance of cure.
Allogeneic stem cell transplantation
For selected patients with high-risk CLL and adequate organ
function as well as a suitable donor, allo HSCT may be the
best option for prolonged survival and possible cure. The po-
tential for long-term disease-free progression (OS 41–65% at
4–5 years [22–27]; see Table 1) must be balanced against the
significant risk of chronic graft-versus-host disease (cGVHD;
44–65%) with associated morbidity and the risk of treatment-
related mortality (TRM). This risk/benefit analysis is based on
factors related to disease, patient, and donor [28]. Chronic
lymphocytic leukemia with poor initial response to a purine
analog-based regimen (<PR or relapse within 12 months from
response) or progression within 24 to 36months of CIT (FCR,
BR, or other anti-CD20-based regimen) identifies high-risk
patients [29]. However, the most recent American Society
for Blood and Marrow Transplantation (ASBMT) guidelines
no longer recommend considering these patients for allograft
evaluation in the absence of high-risk FISH mutations (17p
deletion, TP53 mutation, or 11q deletion) [30]. Instead, novel
agent therapy is proposed for these patients representing a
change from previous European Blood and Marrow
Transplant guidelines. Patients relapsing who have evidence
of clonal evolution and/or complex karyotype, or with del
(11q) with suboptimal response or del (17p), should be eval-
uated for transplant [31]. Novel agents are recommended first
in this setting, but emerging data suggest shorter durations of
response in patients with del (17p) or complex karyotypes and
limited salvage options after failure of novel agents such that
allo HSCT should be entertained ideally prior to loss of dis-
ease control by novel agents.
Patient selection for allo HSCT is also based on careful
consideration of comorbidities that affect TRM and availabil-
ity of a suitable donor (ideally either a matched sibling or fully
matched unrelated donor). The use of reduced-intensity con-
ditioning (RIC) regimenswith lower TRMmay extend the age
eligibility for suitable patients. The integration of novel agents
into the pre- or post-transplant setting of allo HSCT is also
under investigation. Published data have suggested that
ibrutinib may be used safely both pre- and post-allo HSCT
[32].While phase 3 data are lacking, the benefits of allo HSCT
in high-risk CLL patients in prolonging PFS have been shown









Toze 2012 [26] Hebenstreit 2014
[27]
N 90 86 136 76 49 50
Median age
(years)
53 58 56 55 54 58
PFS 42% at 4 years 36% at 5 years 32% at 5 years 43% at 5 years 49% at 5 years 63% at 4 years
OS 65% at 4 years 51% at 5 years 41% at 5 years 63% at 5 years 55% at 5+ years 51% at 4 years
Relapse 40% at 4 years 39% at 3 years 36% at 5 years 40% at 5 years 16% at 5 years and 22% at
15 years
37% at 4 years
Extensive
cGVHD
55% at 2 years 56% at 5 years 51% 65% at 2 years 57% at 5 years 44%
NRM 23% at 4 years 17% at 1 year 32% at 5 years 16% at 5 years 36% at 10 years 30% at 4 years
Predictors for PFS and OS were CR and absence of bulky disease (lymph nodes >5 cm)
cGVHD chronic graft-versus-host disease, NRM nonrelapse mortality
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in several studies (Table 1). However, these studies were com-
pleted before the use of novel agents, and it is not known if
these results will hold in the current setting.
The ASBMT guidelines recommend allo HSCT (a) for
standard-risk CLL in the absence of response or if there is
evidence of disease progression after BCR inhibitors, (b) for
high-risk CLL after failing two lines of therapy and showing
an objective response to BCR inhibitors or to a clinical trial or
for patients who fail to show an objective response or progress
after BCR inhibitors and receive B cell lymphoma-2 (BCL-2)
inhibitors regardless of whether an objective response is
achieved, and (c) for Richter’s transformation upon demon-
stration of an objective response to anthracycline-based che-




The molecule ibrutinib was developed as an oral irreversible
inhibitor of BTK, an intracytoplasmic enzyme in the BCR
signaling pathway that is required for BCR activation of
integrins and other molecules. Congenital mutations or ab-
sence of BTK in humans leads to profound deficiency of B
lymphocytes due to arrest in B cell development with conse-
quent agammaglobulinemia. In CLL, BCR signaling is aber-
rantly activated, promoting B cell proliferation and survival as
well as modulating migration and homing of malignant cells.
The anti-tumor activity of ibrutinib (Table 2) results from dis-
ruption of BCR signaling as well as targeting of toll-like re-
ceptor signaling and adhesion and migration pathways.
An initial phase 1b/2 clinical trial in relapsed/refractory
CLL [20] studied the safety, efficacy, and pharmacokinetics
of ibrutinib. Eighty-five patients with a median of 4 (1–12)
prior therapies, almost all exposed to a purine nucleoside and
rituximab, were treated with ibrutinib at a dose of 420 mg
(n = 51) or 840 mg (n = 34). Deletion 17p was present in
33% and del (11q) in 36%. The overall response rate (ORR)
was 71% at both dose levels, and responses were independent
of adverse cytogenetics. At 26 months, PFS for the entire
cohort was 75% and OS 83%. The responses were predomi-
nantly partial with the observation of an early transient in-
crease in lymphocytes, with frequent persistent peripheral
lymphocytosis, despite regression of adenopathy and spleno-
megaly and improvement in other hematologic values. This
phenomenon of an early rise in lymphocyte count has been
attributed to dislodging of CLL cells from nodal compart-
ments into the circulation. The recognition that persistent or
increased lymphocytosis is not indicative of treatment failure
with these agents has necessitated a revision of response
criteria with the addition of partial response with lymphocy-
tosis (PRL) [33]. Based on the results of these early phase
studies, ibrutinib received FDA-accelerated approval in re-
lapsed CLL in 2014 [34], then was accepted as a breakthrough
drug for CLL with 17p deletion the same year [35]. This study
established the 420-mg daily dose for subsequent trials with
identical BTK occupancy at 96 to 99% for both the 420- and
840-mg doses [36].
The efficacy of ibrutinib was confirmed in the
RESONATE™ trial, a phase 3 comparison of ibrutinib to
ofatumumab in patients with relapsed or refractory CLL with
PFS as the primary endpoint [37]. Eligibility criteria included
at least one prior therapy and ineligibility for purine analog
treatment due to comorbidities, age over 70 years, presence of
del (17p), or short duration of response after CIT. In this mul-
ticenter study, 391 patients were randomly allocated to receive
ibrutinib 420 mg daily until disease progression (n = 195) or
ofatumumab at an initial dose of 300 mg, followed by
2000mgweekly for 7 weeks, then every 4 weeks for 16weeks
(n = 196). The baseline characteristics were well balanced
with a median of 3 (1–12) prior therapies in the ibrutinib group
and 2 (1–13) in the ofatumumab group; del (17p) and del
Table 2 Trials involving new agents
Drug Phase Number Prior lines of
therapy (median)
ORR CR PFS p Value
Ibrutinib [20] 1b/2 85 4 71% 2% 75% at 26 months n/a
Ibrutinib vs. ofatumumab [37] 3 391 3 42.6 vs. 4.1% 2 vs. 1% Not reached vs. 8.1 months p < 0.001 for ORR
Ibrutinib [38] 1b/2 101a 4 90% 7% 69% at 30 months n/a
Idelalisib + rituximab vs.
placebo + rituximab [52]
3 220 Anti-CD20-based
or ≥2 previous
81 vs. 13% 0% Not reached vs. 5.5 months p < 0.001 for ORR
Venetoclax [60] 1 56 4 84% 21% CR/Cri n/a n/a
Venetoclax [61] 1 116 3 79% 20% 25 months n/a
Venetoclax [63] 2 107 2 79% 8% Not reached at 12.1 months n/a
Venetoclax + rituximab [62] 1 49 2 84% 41% CR/Cri n/a n/a
a Relapsed/refractory CLL patients only
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(11q) were each detected in about 30% of patients in both
arms. The study was terminated after a pre-planned interim
analysis demonstrated markedly improved outcomes for the
ibrutinib arm.With a median follow-up of 9.4 months, median
PFS in the ofatumumab arm was 8.1 months and had not been
reached in the ibrutinib arm with a HR for progression or
death in the ibrutinib arm of 0.22 (p < 0.001). A crossover
design permitted patients progressing on ofatumumab to re-
ceive ibrutinib once the primary endpoint was reached, and at
the time of analysis, 57 patients had crossed over to ibrutinib.
Nonetheless, an OS advantage for the ibrutinib therapy was
observed in both uncensored and censored for crossover
groups (HR for death in ibrutinib arm 0.39 and 0.43, respec-
tively, at 12 months; OS 90% in ibrutinib group and 81% in
ofatumumab group). Improvement in PFS was observed
across all subgroups regardless of age, clinical stage, IGHV
mutation status, or presence of del (17p).
An update of the initial phase 1b/2 trial reported 3-year
follow-up of 31 treatment-naïve (TN) patients and 101 pa-
tients with relapsed/refractory CLL treated with single-agent
ibrutinib [38]. At a median of 30 and 23 months on study for
TN and relapsed/refractory patients, 81 and 53%, respectively,
remained on drug. Response quality improved with time; with
extended follow-up, 94% of patients who achieved PRL con-
verted to CR or PR. Discontinuation due to disease progres-
sion was only 3% in the TN group but 21% in the relapsed/
refractory group, whereas discontinuation due to drug intoler-
ance was similar in both groups (10 and 12%, respectively).
The estimated PFS at 30 months was 96 and 69% for the two
groups but only 48% in patients with del (17p).
The toxicities observed with ibrutinib are modest, with the
majority of reported adverse events (AEs) being grade 1–2.
The most frequent nonhematologic AEs occurring in at least
20% of patients were diarrhea, bleeding, fatigue, pyrexia, and
nausea. In the RESONATE study, AEs of grade 3 or higher in
the ibrutinib arm included atrial fibrillation (AF) in 3%, al-
though subsequent reports noted increasing AF prevalence
with additional time on ibrutinib [39]. Another study found
that about 6% of all newly diagnosed CLL patients had a
history of AF; in those without such a history, the background
CLL population incidence of AF was about 1% per year [40].
A recent systematic review and meta-analysis found that the
pooled relative risk of AF associated with ibrutinib as com-
pared to the comparator in randomized trials was 3.5 to 3.9,
depending on the model used. The pooled rate of AF among
ibrutinib recipients from all trials examined was 3.3 per 100
person-years [41]. Arrhythmic symptoms or new-onset dys-
pnea in patients receiving ibrutinib should be evaluated clini-
cally, with electrocardiography if appropriate. Ibrutinib thera-
py should be withheld in patients with new-onset or worsen-
ing grade 3 or 4 toxicities and reinitiated at the starting dose
once symptoms have resolved [42]. In the RESONATE,
RESONATE-2, and HELIOS trials, most patients with AF
were able to continue ibrutinib treatment and did not discon-
tinue due to AF [39, 43, 44].
Bleeding-related AEs, most commonly petechiae or ecchy-
moses, have also been reported with ibrutinib (44% with
ibrutinib vs. 12% with ofatumumab in RESONATE), but ma-
jor hemorrhage (grade 3 or higher or requiring red cell trans-
fusion or hospitalization) occurred in only two patients in the
ibrutinib group and three in the ofatumumab group. A study of
single-agent ibrutinib in CLL found that the cumulative inci-
dence of grade ≤2 bleeding-related AEs plateaued by
6 months, suggesting that the risk of bleeding decreases with
continued therapy [45]. Ibrutinib should be withheld for at
least 3 to 7 days pre- and post-surgery depending on the type
of surgery and the risk of bleeding, and vitamin K antagonists
should not be administered concomitantly. If therapeutic anti-
coagulation is required, consider temporarily withholding
ibrutinib until stable anti-coagulation is achieved [42].
As impaired humoral immunity and increased infection
risk resulting from panhypogammaglobulinemia are charac-
teristic of advanced CLL, the effect of BTK inhibition on
normal B cell function in CLL may have clinical relevance.
A study of 86 patients with previously untreated or relapsed/
refractory CLL receiving ibrutinib for at least 12 months [46]
found a progressive decline in serum immunoglobulin G
(IgG) levels, while immunoglobulin A (IgA) levels increased
with treatment. In patients with a ≥50% increase in IgA level,
the infection rate was decreased, suggesting partial immune
recovery with ibrutinib therapy. Patients taking ibrutinib in
RESONATE also experienced increased IgA levels, as well
as sustained improvements in hemoglobin, platelet levels, and
absolute neutrophil count (ANC) compared with patients tak-
ing ofatumumab [47]. Another study found low rates of
treatment-emergent autoimmune cytopenias (AICs) with
ibrutinib treatment, and 19 of 22 patients receiving corticoste-
roids for autoimmune hemolytic anemia at the start of
ibrutinib therapy were able to discontinue them with resolu-
tion of the hemolytic process [48].
Idelalisib
Idelalisib (Table 2) is an orally bioavailable inhibitor of the
delta isoform of PI3K, the predominant PI3K isoform in B
cells. PI3K has limited expression in other hematopoietic
cells, and thus, PI3K inhibition acts as a targeted B cell ther-
apy. As an inhibitor of PI3K signaling downstream from the
BCR in CLL cells, this drug also interrupts BCR signaling
pathways. However, idelalisib may also disrupt the protective
effect of the CLL microenvironment [49] by interfering with
chemokine networks, including CXCR4, CD40, and CD49d
effects on multiple signaling pathways [50]. It was approved
by the FDA in 2014 for the treatment of relapsed CLL in
combination with rituximab [51].
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In phase 1 studies, idelalisib was investigated as a single
a g e n t a n d i n c omb i n a t i o n w i t h m a n y o t h e r
chemoimmunotherapeutic agents in relapsed or refractory
CLL patients. The clinical activity and acceptable toxicity
led to a pivotal phase 3 randomized trial of idelalisib plus
rituximab vs. rituximab plus placebo [52]. Patients were eli-
gible if they had progressed within 24 months of their last
treatment (which must have included an anti-CD20-based
therapy or at least two prior cytotoxic regimens) and were
not candidates for cytotoxic drugs due to impaired marrow
reserve as a consequence of prior myelosuppressive therapy,
or a creatinine clearance <60 mL/min, or a CIRS score >6. Of
the patients, 222 were allocated to treatment with rituximab
375 mg/m2 as an initial dose, followed by 500 mg/m2 every
2 weeks for four doses then every 4 weeks for three doses (for
a total of eight infusions) in combination with either idelalisib
150 mg or placebo twice daily. Patients (median age 71 years)
were stratified by IGHV mutation status and the presence of
del (17p) or TP53 mutation (present in 40%). Baseline char-
acteristics, including hematologic values, CIRS scores, and
number and type of prior therapies, were well balanced. At
24 weeks, 93% of patients in the rituximab-idelalisib group
were progression-free compared to 46% in the rituximab-
placebo arm, and the study was stopped at this pre-specified
point. Median PFS in the rituximab-placebo arm was
5.5 months and had not been reached in the idelalisib with
rituximab cohort (HR for progression or death in the idelalisib
arm, 0.15; 95% confidence interval 0.08 to 0.28; p < 0.001).
This clinical benefit for the combination was observed in all
pre-specified subgroups including high-risk patients with del
(17p) and/or TP53mutation. Updated results of this study [53]
reported a median PFS of 16.6 months in the latter group and
20.3 months in patients without either abnormality.
In this study, the most frequently observed grade 3 or
higher adverse events attributed to idelalisib were diarrhea
(5%) and increases in hepatic transaminases (8%) [53].
Adverse events of any grade included neutropenia (60%),
transaminase elevation (40%), anemia (29%), thrombocytope-
nia (19%), bleeding (14%), pneumonia (10%), rash (10%),
and pneumonitis (6%). Diarrhea/colitis of any grade occurred
in 21% of patients on idelalisib and was managed by drug
interruption, corticosteroids, and symptom management. The
incidence of diarrhea/colitis is underrepresented in the early
publications due to limited time on therapy for most patients at
the time of analysis. Later reports with longer follow-up report
a higher incidence of diarrhea/colitis, an adverse event that
requires careful monitoring and rapid treatment [54]. The dis-
tinct late-onset diarrhea occurs with a median onset of more
than 6 months of therapy and may be associated with colitis
with lymphocytic infiltration on biopsy [55]. This adverse
event requires drug interruption and typically requires steroid
therapy for rapid resolution. Either prednisone or nonabsorb-
able corticosteroids (e.g., budesonide) are generally effective
in ameliorating this condition. Once the diarrhea resolves, the
patient can often be successfully rechallenged with idelalisib
and the steroids tapered off. Hepatic enzyme elevations were
reversible by withholding drug, and idelalisib could be
restarted in most patients without recurrence. Pneumonitis
has also been reported with idelalisib in other studies, includ-
ing fatal cases, without identifiable pathogens and with no
defined mechanism. A 2015 consensus paper summarizes ex-
perience in the management of these more concerning toxic-
ities of idelalisib [56]. During safety monitoring of several
trials of idelalisib in untreated CLL and relapsed low-grade
lymphoma, an increased incidence of serious infection was
observed and these trials were terminated. Health care profes-
sionals were advised of these results by the manufacturer
(Gilead Sciences), and prophylaxis for Pneumocystis carinii
and monitoring for cytomegalovirus reactivation have conse-
quently been mandated during idelalisib treatment [57].
Venetoclax
Venetoclax (Table 2), a BH3 mimetic, is an orally adminis-
tered small molecule that potently inhibits the anti-apoptotic
BCL-2 protein with limited effect on BCLXL, a related anti-
apoptotic protein important for platelet survival. Venetoclax
induces rapid onset apoptosis of CLL cells, apparently inde-
pendently of TP53 function. Analysis of both in vivo and
in vitro results from a phase 1 trial showed that the depth of
clinical responses to venetoclax were also independent of
chromosome 17p deletion, TP53mutation, and TP53 function
[58]. This agent has recently been approved by the FDA for
the treatment of previously treated CLL with 17p deletion in
the USA [59] and is currently being studied in phase 2 and 3
trials.
In an initial phase 1 trial [60], 56 patients with relapsed/
refractory CLL or small lymphocytic lymphoma (SLL), in-
cluding 17 with del (17p), were treated with single-agent
venetoclax. The ORR was 84% (82% in del [17p]) including
rates of 20% CR or CR with incomplete marrow recovery
(Cri). Tumor lysis syndrome (TLS) developed in five patients,
leading to the suspension of the trial to reassess dosing of the
drug. The trial was restarted with a weekly stepwise dosing
schedule with no subsequent observed TLS.
Roberts reported the results of a phase 1 study of
venetoclax in combination with rituximab in 49 patients with
relapsed/refractory CLL [61]. A CR/Cri rate of 41% was ob-
served, including MRD negativity in 65% (13/20) of these
patients (49% [24/49] overall). These responses were
sustained in six patients achieving CR/CRi for up to 21months
after discontinuing treatment. The most frequent grade 3 or
higher AEs were neutropenia (51%), thrombocytopenia
(16%), and anemia (14%), and there was one death due
to TLS.
Ann Hematol
The updated results of the initial phase 1 dose-escalation
study of daily oral venetoclax, including an expansion cohort
of 60 additional patients, have recently been reported [62]. In
the dose-escalation phase, 56 patients with relapsed/refractory
CLL or SLL received daily venetoclax in doses ranging from
150 to 1200 mg. In an expansion cohort of 60 additional
patients, venetoclax was escalated in weekly stepwise incre-
ments to 400 mg daily. Patients enrolled in this study had
received amedian of three prior lines of therapy although none
with prior ibrutinib or idelalisib. Patients with autoimmune
cytopenias were excluded. Pooled ORRs of 71 to 79% were
observed in subgroups with adverse prognostic features in-
cluding fludarabine resistance, del (17p), and unmutated
IGHV. Complete remissions were observed in 20% of the
patients in both cohorts, and 5% had undetectable MRD by
flow cytometry. With a median follow-up of 17 months in the
cohort treated at 400 mg daily, the median PFS could not be
reliably estimated, but the rate of PFS was estimated to be
66% at 15 months with the likelihood that the CR rate would
increase with longer observation. In the expansion cohort fol-
lowing dose-escalation adjustments, no cases of clinical tumor
lysis were observed.
A multicenter, phase 2, single-arm study examined
venetoclax monotherapy (using a stepped-dose schedule) in
relapsed or refractory del (17p) CLL [63]. At a median follow-
up of 12.1 months, an ORR of 79% was achieved (85 of 107
patients), with a CR/Cri of 8%, a nodular PR of 8%, and a PR
of 69%. MRD in peripheral blood was not detectable in 18 of
45 assessed patients. The most common grade 3–4 adverse
events were neutropenia (40%), infection (20%), anemia
(18%), and thrombocytopenia (15%). Serious adverse events
occurred in 55% of patients, irrespective of their relationship
to treatment, with pyrexia, autoimmune hemolytic anemia,
pneumonia, and febrile neutropenia seen most commonly.
Laboratory TLS was reported in five patients during the
ramp-up period (four within the first 2 days of treatment and
one at week 3) but resolved without clinical sequelae.
Despite the lack of clinical TLS after the institution of the
slow stepwise increase in dose of venetoclax, it remains im-
portant to monitor for laboratory abnormalities indicating
TLS, particularly in patients considered at higher risk because
of a significantly elevated blood lymphocyte count (>25 Gi/L)
or those with bulky adenopathy (>5 cm). In appropriate cases,
hospitalization for dose escalations of venetoclax is required.
Discussion
Patient selection for specific agents
Despite the improvement in response rates and disease control
with frontline chemoimmunotherapy in CLL, disease relapse
remains the norm. Although a subset of patients with mutated
IGHV may experience long PFS after CITwith FCR, the ma-
jority of patients will eventually require subsequent therapy.
With the broader availability of newer agents, the challenge
for the clinician is selection and sequencing of these drugs.
Retreatment with FCR may be considered for suitable pa-
tients experiencing an initial PFS exceeding 24 to 36 months;
however, impaired marrow reserve following this treatment
and the emergence of a del (17p) clone may limit the efficacy
of this regimen. In addition, there is significant concern about
the increased risk ofmyelodysplasia with repeated exposure to
fludarabine. In a minority of younger patients, allo HSCT
should be considered a potentially curative approach if a hu-
man leukocyte antigen (HLA)-matched donor is available, but
for most patients, transplantation will not be feasible due to
age and/or comorbidities and many patients will achieve good
results with novel agents in this setting.
While disease relapse characterized by slowly progressive
lymphocytosis may not require immediate reinstitution of
therapy, subsequent treatment decisions will be guided by
the same factors determining initial therapy, including patient
age and concurrent comorbidities, as well as marrow reserve,
which may be impaired as a result of prior treatment. Repeat
cytogenetic assessment should be performed since the pres-
ence of del (17p) is critical to treatment decisions, and the
frequency of this event increases with subsequent relapses.
Current options for treatment with novel drugs have been
reviewed above. In the absence of evidence from randomized
trials directly comparing the agents under discussion, prefer-
ences may be determined by patient characteristics. Ibrutinib,
idelalisib, and venetoclax are all active in relapsed CLL with
del (17p).With respect to depth of response beyondCR,MRD
negativity has been associated with ibrutinib in combination
(18% in the HELIOS trial in combination with BR) [64], but
rarely with ibrutinib monotherapy. Venetoclax has been asso-
ciated with MRD responses when given as monotherapy
(17%) [63]. The impact of achieving this degree of response
onOS in relapsed CLL remains to be established; ibrutinib has
demonstrated conclusive OS benefit in randomized trials
without achieving MRD negativity. The ease of administra-
tion of oral, once-daily ibrutinib vs. the concomitant require-
ment for 8 cycles of intravenous rituximab with oral, twice-
daily idelalisib may be a consideration in favor of ibrutinib for
some patients, as may the option for dose reduction in patients
with comorbidities (although dose reductions for this reason
are based on physician preferences rather than trial data).
Conversely, the need for anti-coagulation therapy or a prior
history of atrial fibrillation may favor idelalisib, depending on
clinician preference. An indirect comparison of ibrutinib
monotherapy and idelalisib plus ofatumumab [65] suggested
a longer PFS and fewer discontinuations with ibrutinib, al-
though a head-to-head trial is required for a true comparison.
In appropriate patients (those who have achieved a lengthy
first remission after CIT), retreatment with CIT remains a
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reasonable option and has the advantage of a short duration of
therapy and a subsequent treatment-free interval.
Resistance, progression, and sequencing
Disease progression occurring in patients after prolonged
treatment with ibrutinib has been associated with poor prog-
nosis and short survival (median 17.6 months after CLL pro-
gression and 3.5 months if Richter’s transformation had oc-
curred) [66]. However, the patients included in this analysis
were from early clinical trials with ibrutinib and had largely
exhausted standard treatment options when they entered the
trials (median of three prior therapies). In an analysis of
RESONATE and RESONATE-2 patients, 23 patients who
had discontinued first- or second-line ibrutinib had not yet
reached a median OS, compared with a median OS of 7–
9 months in 34 patients who discontinued third-line ibrutinib
or beyond [67]. Of the 31 previously untreated patients who
received ibrutinib as initial therapy in the phase 1 trial [68],
only one has been reported with subsequent ibrutinib failure.
Richter’s transformation has been reported as an early com-
plication in the course of therapy with ibrutinib, but typically
in previously treated patients with adverse cytogenetic fea-
tures, including complex karyotype and MYC abnormalities
on FISH; these patients may have had early Richter’s at study
entry. Studies in patients developing resistance to ibrutinib
have identified point mutations in the BTK binding site
C481S, resulting in loss of BTK inhibition, and in the imme-
diate downstream kinase PLCγ2 [69]. A retrospective analy-
sis of 123 CLL patients who discontinued ibrutinib- or
idelalisib-based therapy found that many patients who
discontinued these therapies due to toxicity or progression
responded to other therapies (40% PR + PRL to nonkinase
inhibitors and 60–67% to other kinase inhibitor therapy)
[70]. Preliminary results from an ongoing phase 2 trial also
suggest that venetoclax monotherapy is active in CLL patients
relapsing after idelalisib or ibrutinib [71].
Lenalidomide, an immunomodulatory drug with potent
in vitro activity in CLL, remains under investigation in CLL,
but one randomized study comparing it to chlorambucil was
terminated early due to excess mortality in the lenalidomide
arm [72]. Acalabrutinib, a second-generation BTK inhibitor
that does not irreversibly target alternative kinases, has been
investigated in a phase 1/2 study [73]. A phase 3 study com-
paring this drug to ibrutinib in high-risk patients with relapsed
CLL has been initiated. Clinical trials of other agents includ-
ing XPO1 inhibitors (e.g., selinexor), Syk inhibitors
(fostamatinib and entospletinib), new BTK inhibitors (BGB-
311), and new PI3K inhibitors (buparlisib, duvelisib, and
TGR-1202) are also in progress. The dramatic responses ob-
served with CAR-T cell therapy in small numbers of ad-
vanced, refractory CLL patients suggest the possibility of ef-
fective immunotherapeutic strategies in the future.
Combination therapy
Ibrutinib and idelalisib have each been combined with BR in
phase 3 clinical trials comparing the three-drug combination
with BR alone. In both cases, the addition of the new agent
resulted in significant improvements in outcome [74, 75].
Two-year results for the HELIOS trial, which studied the com-
bination of ibrutinib with BR, found that over a median
follow-up of 25.4 months, the triple combination was superior
to BR alone in PFS (not reached vs. 14.2 months), 2-year PFS
(74.8 vs. 20.9%), CR/Cri (33.9 vs. 7.2%), best ORR at any
time point (87.2 vs. 66.1%), and MRD-negative response
Table 3 Summary of phase 3 trial results in relapsed/refractory CLL
Trial Agents Design Number Median
age
Median PFS (months) Median follow-up
(months)
MRD
REACH [2] FCR vs. FC Open label 552 62.5 30.6 vs. 20.6 months
(p < 0.001)
25 13 vs. 12%
RESONATE [37] Ibrutinib vs. ofatumumab Open label 391 67 Not reached vs.
8.1 months
9.4 n/a
Furman 2014 [52] Idelalisib + rituximab vs.
rituximab
Double-blind 220 71 Not reached vs.
5.5 months
3.8 and 2.9a n/a
HELIOS [74] Ibrutinib + BR vs. BR Double-blind 578 63.5 Not reached vs. 13.3
(p < 0.0001)




Idelalisib + BR vs. BR Double-blind 416 58% <
65 years
23 vs. 11 (p < 0.0001) 12 n/a
COMPLEMENT
2 [19]
Ofatumumab + FC vs. FC Open label 365 61 28.9 vs. 18.8
(p = 0.0032)
34 21 vs. 8%
(p = 0.0006)
Jones 2016 [76] Idelalisib + ofatumumab vs.
ofatumumab
Open label 261 67 16.4 vs. 8.0
(p < 0.0001)
12.3 n/a
a Time receiving study drug
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(18.0 vs. 4.8% in the intent-to-treat population). Median OS
remained unreached in both treatment arms and there were no
new safety findings [64].
The combination of idelalisib and ofatumumabwas compared
with ofatumumab alone in an open-label phase 3 study in 261
patients with relapsed CLL [76] (Table 3). The combination
demonstrated superior median PFS (16.4 vs. 8.0 months;
p < 0.0001) and ORR (75.3 vs. 18.4%; p < 0.0001).
The combination of idelalisib and entospletinib was tested
in a phase 2 trial and produced an ORR of 60% in relapsed
CLL patients with a median treatment exposure of 10 weeks.
However, the study was terminated early due to treatment-
emergent pneumonitis in 18% of patients (12 cases, 11 of
which were severe), resulting in two fatalities [77].
The combination of ibrutinib and FCR was studied as first-
line therapy in young, fit CLL patients in a phase 2 trial. Early
results in 17 restaged patients showed an ORR of 100% after a
median of 7.7 months of therapy, 8 patients (47%) with CR or
CRL, all of whom were MRD-negative, and 9 (53%) with PR
[78].
A number of other combination regimens involving agents
discussed above are in ongoing clinical trials in CLL patients.
Regimens under investigation include ibrutinib plus
obinutuzumab, ibrutinib plus lenalidomide, ibrutinib plus
lenalidomide plus rituximab, ibrutinib plus selinexor, and
venetoclax plus ibrutinib plus obinutuzumab. The combination
of venetoclax and sunitinib may also be worth investigating,
based on the results of an in vitro study that found that sunitinib
may overcome venetoclax resistance in some patients by down-
regulating BCL-xl, Mcl-1, and A1 in CLL cells [79].
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